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Mapping 123 million neonatal, infant and 
child deaths between 2000 and 2017
Since 2000, many countries have achieved considerable success in improving child survival, but localized progress 
remains unclear. To inform efforts towards United Nations Sustainable Development Goal 3.2—to end preventable child 
deaths by 2030—we need consistently estimated data at the subnational level regarding child mortality rates and trends. 
Here we quantified, for the period 2000–2017, the subnational variation in mortality rates and number of deaths of 
neonates, infants and children under 5 years of age within 99 low- and middle-income countries using a geostatistical 
survival model. We estimated that 32% of children under 5 in these countries lived in districts that had attained rates of 25 
or fewer child deaths per 1,000 live births by 2017, and that 58% of child deaths between 2000 and 2017 in these countries 
could have been averted in the absence of geographical inequality. This study enables the identification of high-mortality 
clusters, patterns of progress and geographical inequalities to inform appropriate investments and implementations that 
will help to improve the health of all populations.
Gains in child survival have long served as an important proxy meas-
ure for improvements in overall population health and development1,2. 
Global progress in reducing child deaths has been heralded as one of 
the greatest success stories of global health3. The annual global num-
ber of deaths of children under 5 years of age (under 5)4 has declined 
from 19.6 million in 1950 to 5.4 million in 2017. Nevertheless, these 
advances in child survival have been far from universally achieved, 
particularly in low- and middle-income countries (LMICs)4. Previous 
subnational child mortality assessments at the first (that is, states or 
provinces) or second (that is, districts or counties) administrative level 
indicate that extensive geographical inequalities persist5–7.
Progress in child survival also diverges across age groups4. Global 
reductions in mortality rates of children under 5—that is, the under-5 
mortality rate (U5MR)—among post-neonatal age groups are greater 
than those for mortality of neonates (0–28 days)4,8. It is relatively 
unclear how these age patterns are shifting at a more local scale, pos-
ing challenges to ensuring child survival. To pursue the ambitious 
Sustainable Development Goal (SDG) of the United Nations9 to “end 
preventable deaths of newborns and children under 5” by 2030, it is 
vital for decision-makers at all levels to better understand where, and 
at what ages, child survival remains most tenuous.
Precision public health and child mortality
Country-level estimates facilitate international comparisons but mask 
important geographical heterogeneity. Previous assessments of mortal-
ity of children under 5 have noted significant within-country heteroge-
neity, particularly in sub-Saharan Africa5,7,10–14, as well as in Brazil15, 
Iran16 and China17. Understanding public health risks at more granular 
subpopulation levels is central to the emerging concept of precision 
public health18, which uses “the best available data to target more effec-
tively and efficiently interventions…to those most in need”18. Efforts 
to produce high-resolution estimates of mortality of children under 5, 
determinants at scales that cover the multiple countries are emerging, 
including for vaccine coverage19,20, malaria21, diarrhoea22 and child 
growth failure23,24. In a previous study, we produced comprehensive 
estimates of African child mortality rates at a 5 × 5-km scale for 5-year 
intervals5. For areas outside of Africa, in which 72% of the world’s chil-
dren live and 46% of global child deaths occurred in 20174, subnational 
heterogeneity remains mostly undescribed25.
Here we produce estimates of death counts and mortality rates of chil-
dren under 5, infants (under 1 years of age) and neonates (0–28 days) 
in 99 countries at policy-relevant subnational scales (first and second 
administrative levels) for each year from 2000 to 2017. We fit a geo-
statistical discrete hazards model to a large dataset that is composed 
of 467 geo-referenced household surveys and censuses, representing 
approximately 15.9 million births and 1.1 million deaths of children 
from 2000 to 2017. Our model includes socioeconomic, environmental 
and health-related spatial covariates with known associations to child 
mortality and uses a Gaussian process random effect to exploit the 
correlation between data points near each other across dimensions of 
space, time and age group, which helps to mitigate the limitations asso-
ciated with data sparsity in our estimations. For this study, we report 
U5MR as the expected number of deaths per 1,000 live births, reflecting 
the probability of dying before the age of 5 for a given location and year.
Unequal rates of child mortality
The risk of a newborn dying before their fifth birthday varies tremen-
dously based on where in the world, and within their country, they are 
born. Across the 99 countries in this study, we estimate that U5MR 
varied as much as 24-fold at the national level in 2017, with the highest 
rate in the Central African Republic of 123.9 deaths (95% uncertainty 
interval, 104.9–148.2) per 1,000 live births, and the lowest rate in Cuba 
of 5.1 deaths (4.4–6.0)4. We observed large subnational variation within 
countries in which overall U5MR was either high or comparatively 
low. For example, in Vietnam, rates across second administrative units 
(henceforth referred to as ‘units’) varied 5.7-fold, from 6.9 (4.6–9.8) in 
the Tenth District in Hồ Chí Minh City to 39.7 (28.1–55.6) in Mường 
Tè District in the Northwest region (Figs. 1b, 2).
Decreases in U5MR between 2000 and 2017 were evident to some 
extent throughout all units (Figs. 1a, b, 2). No unit showed a significant 
increase in U5MR in this period, and in most units U5MR decreased 
greatly, even in units in which the mortality risk was the highest. Out 
of 17,554 units, 60.3% (10,585 units) showed a significant (defined 
as 95% uncertainty intervals that did not overlap) decrease in U5MR 
between 2000 and 2017. Across units in 2000, U5MR ranged from 7.5 
(5.0–10.6) in Santa Clara district, Villa Clara province, Cuba, to 308.4 
(274.9–348.4) in the Sabon Birni Local Government Area of Sokoto 
State, Nigeria. By 2017, the unit with the highest estimated U5MR 
across all 99 countries was Garki Local Government Area, Jigawa state, 
Nigeria, at 195.1 (158.6–230.9). Overall, the total percentage of units 
with a U5MR higher than 80 deaths per 1,000 live births decreased from 
28.9% (5,070) of units in 2000 to 7.0% (1,236) in 2017. Furthermore, 
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32% of units, representing 11.9% of the under-5 population in the 99 
countries, had already met SDG 3.2 for U5MR with a 90% certainty 
threshold (Fig. 1c). For neonatal mortality, 34% of units met the target 
of ≤12 deaths per 1,000 live births (Extended Data Fig. 1). Within 
countries, successes were mixed in some cases. For example, Colombia, 
Guatemala, Libya, Panama, Peru and Vietnam had all achieved SDG 
3.2 for U5MR at the national level by 2017, but each country had units 
that did not achieve the goal with 90% certainty (Fig. 1c).
Successful reductions in child mortality were also observed through-
out entire countries. For example, in 43 LMICs across several world 
regions, the worst-performing unit in 2017 had a U5MR that was lower 
than the best-performing unit in 2000 (Fig. 2). Nearly half of these 
countries were in sub-Saharan Africa. Rwanda showed notable progress 
during the study period, reducing mortality from 144.0 (130.0–161.6) 
in its best-achieving district in 2000 (Rubavu) to 57.2 (47.4–72.1) in 
its worst-achieving district in 2017 (Kayonza). These broad reduc-
tions in U5MR have also led to a convergence of absolute subnational 
geographical inequalities, although relative subnational inequalities 
appear to be mostly unchanged between 2000 and 2017 (Fig. 2 and 
Supplementary Fig. 6.12). Despite this success, the highest U5MRs in 
2017 were still largely concentrated in areas in which rates were highest 
in 2000 (Fig. 1a, b). We observed estimated U5MR ≥ 80 across large 
geographical areas in Western and Central sub-Saharan Africa, and 
within Afghanistan, Cambodia, Haiti, Laos and Myanmar (Fig. 1b).
Deaths of neonates (0–28 days of age) and post-neonates (28–364 
days of age) have come to encompass a larger fraction of overall mor-
tality of children under 5 in recent years. By 2017 (Fig. 1d), neonatal 
mortality increased as a proportion of total deaths of children under 
5 in 91% (90) of countries and for 83% (14,656) of units compared to 
2000. In almost all places where U5MR decreased, the share of the 
mortality burden increased in the groups of children with younger ages. 
Similarly, the mortality of infants (<1 year) has increased relative to 
the mortality for children who are 1–4 years of age in many areas. For 
example, in the Diourbel Region, Senegal, infant mortality constituted 
54.4% (52.4–56.6) of total mortality of children under 5 in 2000; by 
2017, the relative contribution of infant mortality was 73.2% (70.3–
75.8). This shift towards mortality predominantly affecting neonates 
and infants was not as evident in all locations; mortality for children 
aged 1–4 years was responsible for more than 30% of overall under-5 
deaths in 13% (2,226) of units, mostly within high-mortality areas in 
sub-Saharan Africa.
Distribution of under-5 deaths may not follow rates
The goal of mortality-reduction efforts is ultimately to prevent prema-
ture deaths, and not just to reduce mortality rates. Across the countries 
studied here, there were 3.5 million (41%) fewer deaths of children 
under 5 in 2017 than in 2000 (5.0 million compared to 8.5 million). At 
the national level, the largest number of child deaths in 2017 occurred 
in India (1.04 (0.98–1.10) million), Nigeria (0.79 (0.65–0.96) million), 
Pakistan (0.34 (0.27–0.41) million) and the Democratic Republic of 
the Congo (0.25 (0.21–0.31) million) (Fig. 3a). Within these countries, 
the geographical concentration of the deaths of the children varied. In 
Pakistan, over 50% of child deaths in 2017 occurred in Punjab province, 
which had a U5MR of 63.3 (54.1–76.0) deaths per 1,000 live births 
(Fig. 3b). By contrast, 50% of child deaths in the Democratic Republic 
of the Congo in 2017 occurred across 9 out of 26 provinces. Such 
findings are in a large part artefacts of how borders are drawn around 
various at-risk populations (the provinces above account for 53% and 
63%, respectively, of the under-5 population that is at risk in these two 
countries), but can have a real impact at the level at which planning 
occurs. Some concentrated areas with apparent high absolute numbers 
of deaths highlighted by local-level estimates become less noticeable 
when reporting at aggregated administrative levels; for example, areas 
across Guatemala, Honduras and El Salvador are visually striking hot-
spots in Fig. 3d, but less so in Fig. 3b, c.
Our estimates indicate that targeting areas with a ‘high’ U5MR of 
80 will have a lower overall effect than in previous years owing to 
the reductions in mortality rates. In 2000, 23.7% of child deaths— 
representing 2.0 (1.7–2.4) million deaths—occurred in regions in which 
U5MR was less than 80 that year (Fig. 4). By comparison, in 2017, 
69.5% of child deaths occurred in areas in which U5MR was below 80. 
A growing proportion of deaths of children under 5 are occurring in 
‘low’-mortality areas; 7.3% (5.1–10.2) of all deaths of children under 5 
in 2017 occurred in locations in which the U5MR was below the SDG 
3.2 target rate of 25, compared to 1.2% (0.9–1.6) in 2000. For instance, 
Lima, Peru, has a U5MR in the 8th percentile of units in this study, yet 
it ranks in the 96th percentile of highest number of deaths of children 
under 5.
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Fig. 1 | U5MR estimates in 99 LMICs. a, U5MR at the second 
administrative level in 2000. b, U5MR at the second administrative level 
in 2017. c, Modelled posterior exceedance probability that a given second 
administrative unit had achieved the SDG 3.2 target of 25 deaths per 
1,000 live births for children under 5 in 2017. d, Proportion of mortality 
of children under 5 occurring in the neonatal (0–28 days) group at the 
second administrative level in 2017.
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Despite population growth, child deaths have declined due to the 
outpaced decline in U5MR. For example, there were a total of 8.5 
(7.2–10.0) million deaths of children under 5 in the countries in this 
study in 2000; had the 2017 under-5 population been exposed to the 
same U5MRs that were observed in 2000, there would have been 10.6 
(9.0–12.5) million deaths in 2017. Instead, we observed 5.0 (3.8–6.6) 
million deaths in 2017 (Extended Data Fig. 5).
Finally, we combine estimates of subnational variation in mortality 
rates and populations to gain a better understanding of the impact 
of geographical inequality. Overall, 2.7 (2.5–2.9) million deaths, or 
54% of the total number of deaths of children under 5, would have 
been averted in 2017 had all units had a U5MR that matched the best- 
performing unit in each respective country (Extended Data Fig. 2). 
Over the 2000–2017 period, this number is 71.8 (68.5–74.9) million 
deaths, or 58% (55–61) of the total number of deaths of children under 
5. Total deaths attributable to inequality in this scenario ranged from 
13 (6–24) deaths in Belize to 0.84 (0.72–0.99) million deaths in India. 
Furthermore, had all units met the SDG 3.2 target of 25 deaths per 
1,000, an estimated 2.6 (2.3–2.8) million deaths of children under 5 
would have been averted in 2017.
Discussion
This study offers a comprehensive, geospatially resolved resource for 
national and subnational estimates of child deaths and mortality rates 
for 99 LMICs, where 93% of the world’s child deaths4 occurred in 2017. 
Gains in child survival varied substantially within the vast majority of 
countries from 2000 to 2017. Countries such as Vietnam, for example, 
showed more than fivefold variation in mortality rates across second 
administrative-level units. The inconsistency of successes, even at 
subnational levels, indicates how differences in health policy, finan-
cial resources, access to and use of health services, infrastructure, and 
economic development ultimately contribute to millions of lives cut 
short25–27. By providing detailed maps that show precisely where these 
deaths are estimated to have occurred, we provide an important evi-
dence base for looking both to the past, for examples of success, and 
towards the future, in order to identify where precision public-health 
initiatives could save the most lives.
The epidemiological toll of child mortality should be considered both 
in terms of total deaths and as rates of mortality. Focusing only on 
mortality rates can effectively mask areas in which rates are compara-
tively low but child deaths are high owing to large population sizes. The 
number of deaths that occur in high-risk areas has declined, and most 
under-5 deaths in recent years have occurred in lower-risk areas. This 
‘prevention paradox’28 could indicate that whole-population interven-
tions could have a larger overall impact than targeting high-risk areas29. 
At the same time, strategies that target resources to those locations that 
have the highest number of child deaths risk leaving behind some of 
the world’s most marginalized communities: remote, more-sparsely 
populated places in which, relative to the number of children born 
each year, a large number of children die before their fifth birthday. 
Instead, by considering subnational measures of both counts and rates 
of deaths of children under 5, decision-makers can better tailor child 
health programs to align with local contexts, norms and needs. Rural 
communities with high rates but low counts may benefit from ‘last-
mile’ initiatives to provide effective health services to populations who 
lack adequate access to care. By contrast, locations with low rates but 
high counts may require programs that focus on alleviating the cost of 
care, unsafe environmental exposures or health risks that are uniquely 
associated with urban slums30. The SDGs have pointed the global 
development agenda towards progress in child survival. Our analysis 
indicates that reaching the SDG 3.2 targets of 25 child deaths per 1,000 
live births and 12 neonatal deaths per 1,000 live births will require 
only modest improvements or have already been achieved by some 
units; however, these targets are ambitious for other units in which 
child mortality remains high. It is worth noting that many countries 
contain areas that fit both of these profiles. For example, 11 countries 
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Fig. 2 | Geographical inequality in U5MR across 99 countries for 2000 
and 2017. a, Absolute inequalities. Range of U5MR estimates in second 
administrative-level units across 99 LMICs. b, Relative inequalities. Range 
of ratios of U5MR estimates in second administrative-level units relative 
to country means. Each dot represents a second administrative-level unit. 
The lower bound of each bar represents the second administrative-level 
unit with the lowest U5MR in each country. The upper end of each bar 
represents the second administrative-level unit with the highest U5MR 
in each country. Thus, each bar represents the extent of geographical 
inequality in U5MRs estimated for each country. Bars indicating the 
range in 2017 are coloured according to their Global Burden of Disease 
super-region. Grey bars indicate the range in U5MR in 2000. The diamond 
in each bar represents the median U5MR estimated across second 
administrative-level units in each country and year. A coloured bar that is 
shorter than its grey counterpart indicates that geographical inequality has 
narrowed.
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had at least 1 unit that had already met SDG 3.2 with high certainty, 
and at least 1 unit that had not. Subnational estimates can empower 
countries to benchmark gains in child survival against their own sub-
national exemplars as well as advances that have been achieved by their 
peers. Through our counterfactual analysis we showed that even if all 
units had met the SDG 3.2 goal in 2017, there would still have been 
2.4 million deaths of children under 5, indicating that ‘ending pre-
ventable child deaths’ is more complex than simply meeting a target 
threshold. Future research efforts must address the causes of child mor-
tality in local areas and more precisely identify causes of child deaths 
that are amenable to intervention. To that end, new and innovative 
data-collection efforts, such as the ongoing Child Health and Mortality 
Prevention Surveillance network, offer promising prospects by applying 
high-validity, pathology-based methods alongside verbal autopsies to 
determine the cause of death31.
This study offers a unique platform to support the identification of 
local success stories that could be replicated elsewhere. In Rwanda, 
for example, the highest U5MR at the district level in 2017 was 60.2% 
(52.0–67.8%) lower than the lowest U5MR at the district level in 2000. 
Such gains have been partially credited to focused investments in 
the country’s poorest populations, expanding the Mutuelles de santé 
insurance program, and developing a strong workforce of community 
health workers who provide evidence-based treatment and health pro-
motion32,33. Nepal and Cambodia are among the exemplars for consid-
erably decreasing subnational inequalities in child survival since 2000. 
In an era when narrowing disparities within countries is as important 
as reducing national-level gaps, these results provide the evidence base 
to inform best practices and stimulate national conversations about 
related social determinants.
Neonatal mortality rates have also declined but failed to keep pace 
with reductions in mortality rates of older children, leading to a higher 
proportion of deaths of children under 5 occurring within the first four 
weeks of life: from 37.4% (37.1–37.7) in 2000 to 43.7% (43.1–44.3%) in 
2017. This trend is probably related to the increase in scale of routine 
programs and improved infrastructure (for example, vaccination34, and 
water and sanitation35) and the introduction of effective interventions 
to target communicable diseases (for example, malaria control36 and 
prevention of mother-to-child transmission of HIV37). These inter-
ventions have tended to target amenable causes of mortality that are 
more common in older children under 5 rather than dominant causes 
of neonatal mortality, such as prematurity and congenital anomalies38. 
Notably, irrespective of income level or location, some causes of neo-
natal death (for example, chromosomal anomalies and severe preterm 
birth complications) remain difficult to prevent completely with cur-
rent medical technologies. Ultimately, large gains in neonatal mortal-
ity will require serious investment in health system strengthening39. 
Affordable approaches to preventing the majority of neonatal deaths 
in LMICs exist and there are success stories with lessons learned to 
apply40–44, but decisions about which approaches to take must be based 
on the local epidemiological and health system context. In the absence 
of spatially detailed cause of death data, subnational neonatal mortality 
estimates can indicate dominant causes and thus serve as a useful proxy 
to guide prioritization of interventions45.
The accuracy and precision of our estimates were primarily deter-
mined by the timeliness, quantity and quality of available data. In Sri 
Lanka, for example, there were no available surveys, and the wide 
uncertainty intervals surrounding estimates reflect the dearth of availa-
ble evidence in that country (Extended Data Figs. 3, 4). In certain areas, 
this decreased the confidence that we had in claiming that a specific 
subnational area met the SDG 3.2 target (Fig. 1c). This issue is most 
concerning in cases in which estimated mortality rates are high, thus 
helping to identify locations in which it would be most useful to focus 
future data-collection efforts. High mortality rates with large uncer-
tainty intervals were estimated across much of Eastern and Central 
sub-Saharan Africa, and in Cambodia, Laos, Myanmar and Papua New 
Guinea (Extended Data Figs. 3, 4). Furthermore, ongoing conflict in 
countries such as Syria, Yemen and Iraq pose substantial challenges 
to collecting more contemporaneous data, and our estimates may not 
fully capture the effects of prolonged civil unrest or war46,47. Further 
methodological and data limitations are discussed in the Methods.
The accurate estimation of mortality is also a matter of equity; 
highly refined health surveillance is common in high-income coun-
tries, whereas in LMICs, in which rates of child mortality are the high-
est, surveillance that helps to guide investments in health towards the 
areas with the greatest need is less routine48. Ideally, all countries would 
have high-quality, continuous, and complete civil and vital registration 
systems that capture all of the births, deaths and causes of death at 
the appropriate geographical resolution49. In the meantime, analyses 
such as this serve to bridge the information gap that exists between 
low-mortality countries with strong information systems and countries 
that face a dual challenge of weaker information systems and higher 
disease burden.
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Fig. 3 | Estimated number of children under 5 who died within 99 
countries in 2017. a, Number of deaths of children under 5 in each 
country. b, Number of deaths in each first administrative-level unit.  
c, Number of deaths in each second administrative-level unit. d, Number 
of deaths of children under 5 in each 5 × 5-km grid cell. Note that scales 
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By harnessing the unprecedented availability of geo-referenced data 
and developing robust statistical methods, we provide a high-resolution 
atlas of child death counts and rates since 2000, covering countries 
that account for 93% of child deaths. We bring attention to subna-
tional geographical inequalities in the distribution, rates and absolute 
counts of child deaths by age. These high-resolution estimates can help 
decision-makers to structure policy and program implementation and 
facilitate pathways to end preventable child deaths50 by 2030.
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Overview. We fitted a discrete hazards geostatistical model51,52 with correlated 
space–time–age errors and made predictions to generate joint estimates—with 
uncertainty—of the probability of death (the number of deaths per live births) 
and the number of deaths for children aged 0–28 days (neonates), children under 
1 year old (infants) and children under 5 years old at the subnational level for 99 
LMICs for each year from 2000 to 2017. The analytical process is summarized in 
the flowchart in Extended Data Fig. 6. We made estimates at a grid-cell resolution 
of approximately 5 × 5-km and then produced spatially aggregated estimates at 
the first (that is, states or provinces) and second (that is, districts or counties) 
administrative levels, as well as the country level.
Countries were selected for inclusion in this study based on their socio- 
demographic index (SDI) published in the Global Burden of Disease study (GBD)53. 
The SDI is a measure of development based on income per capita, educational 
attainment and fertility rates among women under 25 years old. We primarily aimed 
to include all countries in the middle, low–middle or low SDI quintiles, with several 
exceptions. Brazil and Mexico were excluded despite middle SDI status owing to 
the availability of high-quality vital registration data in these countries, which have 
served as the basis for existing subnational estimates of child mortality. Because this 
study did not incorporate vital registration data sources (see ‘Limitations’), Brazil 
and Mexico were not estimated directly; instead, state-level estimates from the GBD 
2017 study were directly substituted in figures where appropriate4. Albania and 
Moldova were excluded despite middle SDI status owing to geographical disconti-
nuity with other included countries and lack of available survey data. North Korea 
was excluded despite low–middle SDI status owing to geographical discontinuity 
and insufficient data. As countries with high–middle SDI status in 2017, China and 
Malaysia were excluded from this analysis. Libya was included despite high–middle 
SDI status to create better geographical continuity. Island nations with populations 
under 1 million were excluded because they typically lacked sufficient survey data 
or geographical continuity for a geospatial analytic approach to be advantageous 
over a national approach. Supplementary Figure 3.1 shows a map of the countries 
included in this study and Supplementary Table 3.1 lists the countries.
Data. We extracted individual records from 555 household sample survey and 
census sources. Records came in the form of either summary birth histories (SBHs) 
or complete birth histories (CBHs). All input data were subject to quality checks, 
which resulted in the exclusion of 82 surveys and censuses owing to quality con-
cerns (see Supplementary Information section 3.2 for more details). Data on life 
and mortality experiences from CBH sources can be tabulated directly into discrete 
period and age bins, thus allowing for period-specific mortality estimations, known 
as the synthetic cohort method54–56. For SBH data, we used indirect estimation57 to 
estimate age-specific mortality probabilities and sample sizes and assign them to 
specific time periods. Complete details are available in Supplementary Information 
section 3.3.2.
In all cases, after pre-processing, each data point provided a number of deaths 
and a sample size for an age bin in a specific year and location. We referenced 
all data points to GPS coordinates (latitude and longitude) wherever possible. In 
cases in which GPS data were unavailable, we matched data points to the smallest 
possible areal unit (also referred to as ‘polygons’). All polygon data were spatially 
resampled into multiple GPS coordinates and weighted based on the population 
distribution following a previously described procedure5,22,23,58 and described 
in Supplementary Information section 3.4. Our combined global dataset contained 
approximately 15.9 million births and 1.1 million child deaths. A complete list of 
data sources is provided in Supplementary Table 8.1.
In addition to data on child mortality, we used a number of spatial data sources 
for this analysis. These included a suite of geospatial covariates, population esti-
mates and administrative boundaries68. These sources and processing procedures 
are described in Supplementary Information section 4.
Spatial covariates. We extracted values from each of 10 geospatial covariates at 
each data point location. Geospatial covariates are spatial data represented at the 
5 × 5-km grid-cell resolution. The covariates were travel time to the nearest city, 
educational attainment of maternal-aged women, the ratio of population of chil-
dren under 5 to women of reproductive age (ages 15–49 years old), the mass per 
cubic meter of air of particles with a diameter less than 2.5 μm, total population, 
a binary indicator of urbanicity, intensity of lights at night, the proportion of chil-
dren aged 12–23 months who had received the third dose of diphtheria–pertussis– 
tetanus vaccine, incidence rate of Plasmodium falciparum-associated malaria in 
children under 5 and prevalence of stunting in children under 5 (see Supplementary 
Information). All covariate values were centred on their means and scaled by their 
standard deviations. Covariates typically had global spatial coverage and values that 
vary by year. More details of the spatial covariates can be found in Supplementary 
Information section 4.
Analysis. Geostatistical model. To synthesize information across various sources, 
and to make consistent estimates across space and time, we fitted discrete haz-
ards51,52 geostatistical models59 to our data. The models were discrete in the sense 
that ages were represented in seven mutually exclusive bins (0, 1–5, 6–11, 12–23, 
24–35, 36–47 and 48–59 months), each with its own assumed constant mortality 
probability. The model explicitly accounted for variation across age bin, year and 
space through inclusion of both fixed and random effects. Indicator variables for 
each age bin were included to form a discrete baseline mortality hazard function, 
representing the risk of mortality in discrete bins from birth to 59 months of age 
with covariates set at their means. Baseline hazard functions were allowed to vary 
in space and time in response to changing covariate values, as well as in response 
to linear effect on year. To model this relationship, we estimated the effect of each 
covariate value on the risk of mortality. These estimated effects were then applied 
to the gridded surface of covariate values to make predictions across the entire 
study geography. We also included a Gaussian random effect across countries to 
account for larger-scale variations due to political or institutional effects, as well as 
a Gaussian random effect for each data source to account for source-specific biases. 
Finally, we included a Gaussian process random effect with a covariance matrix 
structured to account for remaining correlation across age, time and physical space. 
As such, estimates at a specific age, time or place benefitted from drawing predic-
tive strength from data points nearby in all of these dimensions.
For each modelling region, we fitted one such discrete hazards model with a 
binomial data likelihood. All data were prepared such that we counted or estimated 
the number of children entering into (n) and dying within (Y) each period–age 
bin from each GPS-point location (s) in each survey (k) within each country (c).
The number of deaths for children in age band (a) in year (t) at location (s) was 
assumed to follow a binomial distribution:
~Y n Pbinomial( , )a s t a s t a s t, , , , , ,
where Pa,s,t is the probability of death in age bin a, conditional on survival to that 
age bin for a particular space–time location. Using a generalized linear regression 
modelling framework, a logit link function is used to relate P to a linear combi-
nation of effects:
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The first term, β0, is an intercept, representing the mean for the first age band when 
all covariates are equal to zero, whereas βa
1 are fixed effects for each age band, 
representing the mean overall hazard deviation for each age band from the inter-
cept, when all other covariates are equal to zero. β2 are the effects of geospatial 
covariates (Xs,t), which we describe in detail in Supplementary Information section 
4. β3 is an overall linear temporal effect to account for overall temporal trends 
within the region. All geospatial covariates were centred and scaled by subtracting 
their mean and dividing by their standard deviations. Each v term represents uncor-
related Gaussian random effects: ν σ~ normal(0, )c s[ ] c
2  is a country-level random 
effect applied to all locations (s) within a country (c); ν σ~ normal(0, )k s[ ] k
2  is a data 
source-level random effect for the survey (k) from which the data at location s were 
observed. Data source-level random effects were used to account for systematic 
variation or biases across data sources and were included in model fitting but not 
in prediction from fitted models. The term Za,s,t ~ Gaussian process(0, K) is a 
correlated random effect across age, space and time, and is modelled as a four-di-
mensional mean zero Gaussian process with covariance matrix K. This term 
accounts for structured residual correlation across these spatial–age–temporal 
dimensions that are not accounted for by any of the model’s other fixed or random 
effects. This structure was chosen, because the hazard probability for each age 
group is expected to vary in space and time, and such spatiotemporal correlations 
are likely to be similar across ages. K is constructed as a separable process across 
age, space and time =Σ ⊗Σ ⊗ΣK( )a t s . The continuous spatial component is 
modelled with a stationary isotropic Matérn covariance function, and the age and 
temporal effects were each assumed to be discrete auto-regressive order 1. We 
provide further details on model fitting and specification in Supplementary 
Information section 5.1.
We assigned priors to all model parameters and performed maximum a pos-
teriori inference using Template Model Builder60 software in R version 3.4. We 
fitted the model separately for each of 11 world regions (see Supplementary Fig. 
3.1), owing to memory constraints and to allow model parameters to vary across 
epidemiologically distinct regions.
Post-estimation. Using the joint precision matrix and point estimates, we generated 
1,000 draws from all model parameters using a multivariate-normal approxima-
tion. These model parameter draws were used to predict corresponding draws 
of mortality probabilities across all age groups for each grid cell in each year. In 
other words, for each age bin in each year we estimated 1,000 gridded surfaces of 
mortality probability estimates, each surface corresponding to one draw from the 
posterior parameter estimates61. All subsequent post-estimation procedures were 
carried out across draws to propagate model uncertainty. We used these estimated 
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spatiotemporal gridded surfaces of age-specific mortality probabilities to produce 
various final resulting data products.
From the fitted model parameters, we produced posterior mortality probability 
estimates for each age group for each 5 × 5-km grid cell for each year from 2000 
to 2017. We combined gridded age group estimates to obtain infant (under 1) 
and child (under 5) mortality estimates at each gridded location. Using a con-
version from mortality probability to mortality rates, and using a gridded surface 
of population, we also estimated the number of deaths that occurred in each age 
group at each location in each year. For both mortality probabilities and counts, 
we multiplied out corresponding gridded estimates by a constant to ensure that at 
the national—and in two countries, the first administrative-level unit—aggregated 
estimates for each age group and year were calibrated such that they equalled esti-
mates in the GBD study4. This calibration allowed us to take advantage of national 
data sources, such as vital registration, that could not be used in this study. We also 
aggregated grid-cell-level estimates to first and second administrative-level units 
using gridded population surface to weight estimates. These steps are described 
in Supplementary Information section 5.2.
Model validation. We used fivefold cross-validation to assess and compare model 
performance with respect to estimating local trends of age-specific mortality. Each 
fold was created by combining complete surveys into subsets of approximately 20% 
of data sources from the input data. Holding out entire surveys at a time served 
as a comparable approximation to the type of missingness in our data, essentially 
helping us check how well our model estimates of mortality probabilities compared 
to empirical estimates of mortality probability from an unobserved data source 
that did not inform the model.
For each posterior draw, we aggregated to administrative units. Using data 
aggregated to the administrative unit and aggregated estimate pairs, we calcu-
lated the difference between out-of-sample empirical data estimates and modelled 
estimates, and we report the following summary metrics: mean error, which serves 
as a measure of bias, the square root of mean errors, which serves as a measure of 
the total variation in the errors, the correlation and 95% coverage. At the second 
administrative-level unit for under-5 mortality, our out-of-sample 95% coverage 
was 93%, correlation was 0.78, mean absolute error was 0.015 and mean error was 
−0.0011. These results indicate a good overall fit, with minimal bias. This proce-
dure and the full validation results are discussed in Supplementary Information 
section 5.3.
Limitations. This work should be assessed in full acknowledgement of several 
data and methodological limitations. We exclusively used CBH and SBH data from 
household survey and census data sources. Ideally, estimates of child mortality 
should incorporate all available data, including data from administrative vital 
registration systems. Vital registration systems are commonly present in many 
middle-income and all high-income countries. There are known data-quality issues 
with vital registration sources in many middle-income countries48,62 that add com-
plications to their inclusion in our modelling procedure. For example, systems may 
not capture all deaths, and this level of ‘underreporting’ probably varies in space, 
time and age. In addition, underreporting is probably negatively correlated with 
mortality, and could contribute substantial bias to estimates. Statistical methods 
must be developed to jointly estimate—and adjust for—underreporting in vital 
registration data before such data can be used in geospatial models of child mor-
tality. Promising work has begun in this domain in specific countries63, but further 
advancement will be necessary to improve estimates across a time series and across 
many countries at once.
We assume that SBH and CBH data were retrospectively representative in the 
locations in which they were collected. As such, we assume that survey respond-
ents did not migrate. High-spatial-resolution migration estimates with which to 
adjust estimates do not yet exist, and many of the data sources that we use do 
not collect information on migration. We conducted a focused sensitivity anal-
ysis (Supplementary Information section 5.4.4) for migration in six countries, 
and found that although our results were generally robust, there was variation 
by country. Furthermore, despite providing high-quality retrospective data from 
representative samples of households, birth history data can suffer from certain 
non-sampling issues, such as survival/selection biases64 and misplacement of 
births65. We did not attempt to make corrections to data, and they were used as-is. 
Furthermore, retrospective birth history data will—by design—have a changing 
composition of maternal ages depending on the time since the survey. This was 
minimized by limiting retrospective trends to up to 17 years.
Although we collated a large geo-referenced database of survey data on child 
mortality, these data represented about 1% (1.1 million) of total deaths of children 
under 5 in study areas over the period. Where data do not exist or are not available 
in certain locations, mean estimates are informed from smoothing to nearby 
estimates and covariates. As such, there could be additional small-scale heterogeneity 
that is not picked up by our model. Wider uncertainty intervals in areas with 
no data account for these potential unknowns, and our 95% coverage estimates 
in out-of-sample predictive tests appear to be well-calibrated at the second 
administrative unit level. Furthermore, discrete localized mortality shock events 
could be missing in our analysis due to the lack of data and selection biases in 
surveys and censuses, and spatiotemporal smoothing. Fatal discontinuities are 
explicitly accounted for at the national or province level by calibration to GBD 
estimates. In all, 0.35% (0.4 million) of the 123 million deaths over this period were 
attributed to fatal discontinuities.
On the modelling side, we integrated point and areal data into a continuous 
model by constructing pseudo-points from areal data. Modelling approaches that 
integrate point and areal data as part of a joint model likelihood function are in 
development66 but are currently computationally infeasible at the large geograph-
ical scales at which we currently model. Furthermore, we divided our models into 
11 regional fits (see Supplementary Fig. 3.1), as a full model that encompasses 
all 99 countries would be computationally infeasible due to memory constraints. 
Splitting up modelling in this way had the benefit of enabling parameters to vary 
across epidemiologically distinct world regions. A preferred model, however, would 
be fitted to all data simultaneously with parameters that are spatially variable.
The separable model used for age–space–time correlations is a common par-
simonious assumption afforded in applying spatiotemporal geostatistical models 
due to efficient computation and inference; however, it yields the assumption of 
fully symmetric covariance. The symmetry implicit in the separable model dictates, 
for example, that (holding age constant for simplicity) the covariance between 
the observations at (location 1, time 1) and (location 2, time 2) is the same as the 
covariance between (location 1, time 2) and (location 2, time 1). Given our avail-
able data density in space–age–time, we believe that attempting to parameterize a 
more complex non-separable model would be challenging both computationally 
and inferentially, and it is not clear whether there would be much to benefit from 
the extra complications.
There are several limitations to address with respect to the use of covariates in 
the model. Most of the geospatial covariates that we used in the geostatistical model 
were themselves estimates produced from various geospatial models. Some of those 
estimated surfaces used covariates that were also included in our model in their 
estimation process. As such, we emphasize that our model is meant to be predictive, 
and that drawing inference from fitted coefficients across these highly correlated 
covariates is problematic and not recommended. Furthermore, we assumed no 
measurement error in the covariate values and assumed that the functional form 
between mortality and all covariates was linear in logit space. In certain locations, 
we used covariate values for prediction that were outside the observed range of the 
training data. As we explore in Supplementary Information section 5.4.2, however, 
these areas represent a relatively small proportion of the population.
Finally, we used a method for indirect estimation of SBHs that was recently 
developed and validated57. As such, indirect estimation was carried out as a 
pre-processing step before fitting the geostatistical model. We attempted to prop-
agate various forms of uncertainty that could be introduced in this step, which 
resulted in halving the total effective sample size across all SBH data. In future, we 
aim to fully integrate such processing into the statistical model; such methods are 
in development67, but are not yet computationally feasible at scale.
Reporting summary. Further information on research design is available in 
the Nature Research Reporting Summary linked to this paper.
Data availability
The findings of this study are supported by data that are available from pub-
lic online repositories, data that are publicly available upon request of the data 
provider and data that are not publicly available due to restrictions by the data 
provider. Non-publicly available data were used under a license for the current 
study, but may be available from the authors upon reasonable request and with 
permission of the data provider. A detailed table of data sources and availability 
can be found in Supplementary Table 8.1. The full output of the analyses is publicly 
available in the Global Health Data Exchange (GHDx; http://ghdx.healthdata.org/
record/ihme-data/lmic-under5-mortality-rate-geospatial-estimates-2000-2017) 
and can be explored using custom data visualization tools (https://vizhub. 
healthdata.org/lbd/under5).
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Extended Data Fig. 1 | Neonatal and infant mortality rates in 2017.  
a, b, Maps showing the mortality rates of neonates (a; birth to 28 days of 
age) and infants (b; under 1 year of age) across second administrative-level 
units in 2017. Note that the ranges in the keys are different for the two 
maps.
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Extended Data Fig. 2 | Impact of inequality on U5MR. a, Potential 
reduction in the number of deaths that would have occurred if all second 
administrative-level units in the 20 countries with the greatest number of 
deaths of children under 5 in 2017 realized a homogenous U5MR that was 
equal to that of the lowest observed mortality rate in that country. In total, 
66% of under-5 deaths could have been averted if all countries maintained 
mortality rates equal to the second administrative-level unit with lowest 
mortality. If this reference rate is set to the lowest observed rate across all 
of the 99 countries that were included in this study, 95% of under-5 deaths 
could have been averted. The size of each bar represents the total number 
of under-5 deaths in each country. The red portion of each bar indicates 
the number of deaths ‘attributed’ to geographical inequality in mortality 
rates, whereas the blue portion represents the number of deaths that would 
remain in the scenario in which all second administrative-level units 
within countries had the same mortality rate as the best-performing unit. 
b, Locations of under-5 deaths ‘attributable’ to geographical inequality, 
across all second administrative-level units in each country. Each country 
has one unit highlighted with a green diamond, which is the reference 
unit, or the location with the lowest mortality rate in the country in 2017.
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Extended Data Fig. 3 | Relative uncertainty in U5MR estimates for 2017. 
Relative uncertainty in second administrative-level estimates compared 
with mean estimated U5MRs in each second administrative-level unit 
for 2017. Mean rates and relative uncertainty are split into population-
weighted quartiles. These cut-off points indicate the relative uncertainty 
minimum, 25th, 50th and 75th percentiles, and maximum, which are 
0.29, 0.51, 0.63 and 0.86, and 3.12, respectively. The under-5 mortality 
minimum, 25th, 50th and 75th percentiles, and maximum are 1.4, 13.0, 
22.9 and 44.8, and 190.6 deaths per 1,000 live births. Areas in which our 
estimates are more uncertain are coloured with a scale of increasing blue 
hue, whereas areas in which the mean estimates of U5MR are high are 
coloured with a scale of increasing red hue. Purple areas have high, but 
uncertain, estimates of U5MRs. White areas have low relative mortality, 
with fairly certain estimates. Relative uncertainty is defined as the ratio of 
the width of the 95% uncertainty interval to the mean estimate.
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Extended Data Fig. 4 | Lower and upper uncertainty interval boundaries for U5MR mortality estimates in 2017. a, b, Lower (a) and upper (b) 95% 
uncertainty intervals for U5MR estimates across the second administrative-level units in 99 countries.
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Extended Data Fig. 5 | The counteracting forces of population change and mortality rate decline on total number of under-5 deaths. Arrow plots 
show the mortality rate strata (bins of 10 per 1,000 livebirths) in 2000.
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Extended Data Fig. 6 | Flowchart summarizing analytical process. Standard demographic notation were used. n, length of age bin; x, starting age of age 
bin; d, number of deaths; q, probability of death; a, average time lived in age bin by those who died in the age bin.
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